Abstract: The present invention relates to (meth)acrylamide monomers of the formula: wherein R is H or CH3, R1 is selected from H, substituted and unsubstituted alkyl groups having 1 to 8 carbon atoms, substituted and unsubstituted benzene and toluene groups and and R2, R3 and R4 are independently selected from alkyl groups having 1 to 8 carbon atoms, substituted and unsubstituted benzene and toluene groups, and —OSiR5R6R7 wherein R5, R6 and R7 are independently selected from the group consisting of straight or branched alkyl groups having 1 to 4 carbon atoms. Polymers made therefrom are also disclosed.

Abstract: Aqueous coating compositions containing (1) a first polymer containing reactive functional groups with a selected level of carboxylic acid functionality and (2) a polyfunctional crosslinker agent containing functional groups that are reactive with appropriate functional groups of the first polymer, are disclosed. The two-component polymer compositions provide a combination of durability and ready removability of the final coating after curing. Two-component polymer compositions based on the first polymer containing hydroxyl functionality in addition to carboxylic acid functionality and use of a polyisocyanate as the polyfunctional crosslinker agent are especially useful as floor polish compositions.

Abstract: Multimodal polyolefin polymers may be prepared in series-connected polymerization reactors where a prior reactor is a slurry reactor employing light solvent as the slurry medium and hydrogen to limit polymer molecular weight, the polymer product from the prior reactor being substantially freed of hydrogen prior to entry into a subsequent polymerization reactor operating at low hydrogen pressure to produce a high molecular weight olefin. The economics and operating performance of such a series slurry reactor polyethylene process can be significantly improved through the use of an intermediate slurry transfer system and hydrogen removal apparatus that employs flash drums in series in conjunction with a warm recycle solvent slurry diluent.

Abstract: The present invention pertains to a siliconized polyester resin that has a sufficiently high Tg that the siliconized polyester is a solid at room temperature. The silicone polyester preferably has a Tg of 30° C. or greater. The silicone polyester can be produced as a particulate and remain stable at room temperature. The particulate silicone polyester is suitable for use in coating compositions, including powder coating compositions. The coating can be clear or pigmented, and thus optionally can include pigment. The coating composition also includes a crosslinker. The coating composition can be ground into a powder. The powder is stable at room temperature. The powder is then capable of being coated on a suitable substrate and then baked to form a coated metal object.

Abstract: The invention provides a process for preparing linear organopolysiloxanes (P) having diorganosiloxy units and Si—H groups, in which, in a first step, diorganodichlorosilanes (A) and monochlorosilanes (B) and optionally dichlorosilanes (C), at least one of the monochlorosilanes (B) or dichlorosilanes (C) containing Si—H groups, are reacted with at most 0.5 mol of water per mole of hydrolyzable chlorine to give a partial hydrolyzate (T) and gaseous hydrogen chloride, and, in a second step, the SiCl groups still present in the partial hydrolyzate (T) are removed by treating with water to form hydrochloric acid, and a hydrolyzate (H) containing the organopolysiloxanes (P) is obtained.

Abstract: Disclosed is a process for preparing branched polyarylene ether polymers by (A) providing a reaction mixture comprising (i) a polyfunctional phenol compound of the formula Ar(OH)x wherein x?3 and wherein Ar is an aryl moiety or an alkylaryl moiety, provided that when Ar is an alkylaryl moiety at least three of the —OH groups are bonded to an aryl portion thereof, (ii) a compound of the formula wherein m is 0 or 1, Y and Y? each, independently of the other, is fluorine or chlorine, and A is as defined herein, (iii) a compound of the formula wherein B is as defined herein, and (iv) a carbonate base; and (B) heating the reaction mixture and removing generated water from the reaction mixture, thereby effecting a polymerization reaction. Also disclosed are polymers prepared by this process and imaging members containing these polymers.

Abstract: Poly(trimethylene dicarboxylate) prepared by polycondensation of: (a) 1,3-propanediol; (b) aliphatic or aromatic diacid or diester; and (c) from about 0.01 to about 0.2 mole %, based on the total number of moles of 1,3-propanediol and diacid or ester, of polyfunctional reactant containing three or more carboxylic acid type groups or hydroxy groups. Shaped articles, including bottles, are made from the poly(trimethylene dicarboxylate).

Abstract: The present disclosure relates to the cosmetic use of poly-N-?- and -N-?-lysine and ornithine compounds comprising a thiol function. The disclosure is also directed towards poly-N-?- and -N-?-lysine and ornithine compounds comprising a thiol function and also to cosmetic compositions containing the disclosed compounds.

Abstract: The present invention relates to a novel diamine, a novel acid dianhydride, and a novel composition containing a polyimide produced from such diamine and acid dianhydride. Specifically, the present invention relates to an acid dianhydride that has a photosensitive group bonded through the mediation of an alkylene group or a fluoroalkylene group, a diamine that has a reactive group bonded through the mediation of an alkylene group or a fluoroalkylene group, and a polyimide composition that contains a novel polyimide having at least one of such acid dianhydride residue and diamine residue in a molecule thereof.

Abstract: The present invention provides a sulfonium salt of the formula (Ia) a polymeric compound comprising a structural unit of the formula (Ib) and a chemical amplification type positive resist composition comprising (A) an acid generator comprising at least one compound selected from the group consisting of a sulfonium salt of the formula (Ia), a polymeric compound comprising a structural unit of the formula (Ib), and a sulfonium salt of the formula (Ic); and (B) resin which contains a structural unit having an acid labile group and which itself is insoluble or poorly soluble in an alkali aqueous solution but becomes soluble in an alkali aqueous solution by the action of an acid.

Abstract: A composition for making a high-refractive-index resin contains a polythiol compound and a compound containing at least two iso(thio)cyanato groups, the polythiol compound having a dithioacetal, dithioketal, orthotrithioformic ester, or orthotetrathiocarbonic ester skeleton. The molar ratio of the mercapto group to the iso(thio)cyanato group in the composition is greater than 1.0 but not more than 3.0. A method for making a resin by curing the composition, a resin prepared by curing the composition, an optical element made from the resin, and a lens made from the optical element are also provided.

Abstract: The invention concerns a method for preparing polymers having at least a thiol function, comprising pyrolysis of at least a polymer having at least a function of formula (I), wherein: R1, R2, R3 and R4 are such as defined in the description

Abstract: The epoxy resin curing agent of the present invention comprises a polyamino compound obtainable by addition reaction of aliphatic diamine represented by the formula (1) and styrene and a curing accelerator comprising an organic compound having at least one carboxyl group and at least one hydroxyl group within the molecule, which can achieve a low viscosity without containing environmental harmful substances such as phenol and solvents. In addition, the epoxy resin composition using said epoxy resin curing agent shows an excellent curability at low temperature and it provides a cured coating film having excellent appearance H2N—H2C-A-CH2—NH2??(1) wherein A is a phenylene group or a cyclohexylene group.

Abstract: A preferred way of converting insulin precursors into insulin compounds is to perform an enzymatic peptide cleavage in an aqueous medium and, thereafter, without removal of the intermediate product formed, to add an amino acid ester or a peptide ester and an organic solvent so that the desired coupling takes place.

Abstract: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.

Abstract: This invention discloses endogenous calcineurin inhibitors, Calcipressin, Csp1, Csp2, and Csp3, as shown in SEQ ID Nos: 4-5, or 24. This invention also discloses nucleic acid sequences that can activate or regulate transcription of the CSP family of polypeptides.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: Polypeptide produced from human stromal cell line, the process for the preparation of the polypeptide, DNA encoding the polypeptide, vector carrying the DNA, host cell transformed by the vector, antibody of the polypeptide, and pharmaceutical composition containing the polypeptide or the antibody.

Abstract: The present invention relates to immunogenic Toxoplasma gondii proteins, to T. gondii nucleic acid molecules, including those that encode such proteins and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules and antibodies. Also included in the present invention are compositions comprising such proteins, nucleic acid molecules and/or antibodies, as well as the use of such compositions to inhibit oocyst shedding by cats due to infection with T. gondii. The present invention also includes the use of certain T. gondii-based antisera to identify such nucleic acid molecules and proteins, as well as nucleic acid molecules and proteins identified by such methods. The present invention also relates to novel methods for the detection of cysts and oocysts.

Abstract: This invention provides novel genes and polypeptides of the transient receptor potential channel family, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.

Abstract: This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof.

Abstract: The present invention relates to a novel collagen production method wherein the collagen-containing tissues are fermented to extract the collagen. The fermentation process employs microorganisms, including but is not limited to bacteria and yeast. The present invention is also directed to collagen product comprising collagen produced by fermentation.

Abstract: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.

Abstract: Codon-optimized nucleic acids, polypeptides, and antibodies are described herein.

Abstract: A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.

Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.

Abstract: An ionic polymer is utilized in “recharging” (another layer having a different charge) a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The resulting recharged complex can be formed with an appropriate amount of positive or negative charge such that the resulting complex has the desired net charge.

Abstract: A human protein (designated Carboxy-terminal Modulating protein, CTMP) is described and is identified as having tumour suppressor properties. CTMP has been shown to interact with protein kinase B and inhibit protein kinase B activity, establishing its importance in the protein kinase B signalling pathway.

Abstract: Loblolly pine (Pinus taeda L.) is the most important commercial tree species in the USA harvested for pulp and solid wood products. Increasing the efficiency of chemical pulping may be achieved through the manipulation of genes involved in the lignin biosynthetic pathway. A null allele of cinnamyl alcohol dehydrogenase (CAD) has been discovered in the loblolly pine clone 7-56 which displays altered lignin composition. During identification of single nucleotide polymorphisms (SNPs) in the cad gene, a two-base pair adenosine insertion located in exon five and unique to clone 7-56 was discovered. The sequence mutation causes a frame-shift predicted to result in premature termination of the protein. For routine detection of the mutation, a diagnostic assay was developed utilising Template-directed Dye-terminator Incorporation and Fluorescence Polarization detection (FP-TDI).

Abstract: A pharmaceutical composition comprises the sequence of SEQ ID NO:s 3-5 or pharmaceutically equivalent sequences. Methods employing the pharmaceutical compositions include treatments to increase angiogenesis, to stimulate HIF-1? function, to treat hypoxia-related conditions, and to maintain normal cell functions under hypoxia.

Abstract: A method for sulfonating compounds having one or more free hydroxyl functional groups and/or one or more optionally substituted primary or secondary functional groups, including treating the compounds with a complex of SO3-DMF in the presence of an acid capture agent.

Abstract: The present invention relates to highly hydroxyalkylated, glyoxal crosslinked, purified hydroxyalkyl guar useful as additive in the building industry, and to a method for its preparation.

Abstract: A solid phase synthetic method is disclosed in which the usual solid phase synthetic steps are carried out and the spent solid phase support is reacted to form a volatilizable compound upon cleavage of the reaction product from the solid phase support. The cleaved product is then separated from the volatile compound by volatilization of that compound. Exemplary solid supports that form a volatilizable compound are also disclosed.

Abstract: Provided are fluorescent substrates for ?-lactamases having the general formula I: in which R is a benzyl, 2-thienylmethyl, or cyanomethyl group; R? is selected from the group consisting of H, physiologically acceptable salts or metal, ester groups, ammonium cations, —CHR2OCO(CH2)nCH3, —CHR2OCOC(CH3)3, acylthiomethyl, acyloxy-alpha-benzyl, deltabutyrolactonyl, methoxycarbonyloxymethyl, phenyl, methylsulphinylmethyl, ?-morpholinoethyl, dialkylaminoethyl, and dialkylaminocarbonyloxymethyl, in which R2 is selected from the group consisting of H and lower alkyl; A is selected from the group consisting of S, O, SO, SO2 and CH2; and Z is a donor fluorescent moiety. Also provided are methods of use of the compound of general formula I.

Abstract: The present invention provides processes for preparing calcium salts of statin, particularly rosuvastatin calcium salt substantially free of impurities on an industrial scale.

Abstract: Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one having a diffraction peak at a diffraction angle (2?±0.2°) of 12.8°, 18.1° and/or 23.5° in a powder X-ray diffraction are excellent in stability against light, therefore are suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation.

Abstract: This application discloses a novel process to synthesize 3-amino-4-substituted pyrazole derivatives, which may be used, for example, as intermediates to prepare compounds having, for example, pharmaceutical utility.

Abstract: A process for producing cyclic thioether compounds and their synthetic intermediates. The process produces a compound represented by formula (5): wherein G1 is an alkylene group, R1 is a thiol protecting group, R2 is hydrogen or an amino protecting group, and Ar is an aryl group or a 5- to 7-membered heteroaryl group.

Abstract: The present invention relates to a new method of preparation of the polymorph form 1 of methyl (S)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl-acetate hydrogensulfate of the formula (I)

Abstract: A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. These compounds can be useful as factor Xa inhibitors.

Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.

Abstract: The invention relates to a novel preparation of 3-fluoroquinolines of formula (I) in which R1, R2, R3 and R4 represent: a) a fluorine; b) an alkyl optionally substituted with one to three fluorines, with OR5 in which R5 is an alkyl, a hydrogen or a hydroxyl-protecting group, or with NR?R? in which R? and R? represent an alkyl, a hydrogen or an amino-protecting group; c) OR6 in which R6 represents a hydrogen, a phenol-protecting group or an alkyl, optionally substituted with a fluorine, with OR5 or with NR?R? as defined above; d) NR?1R?1 in which R?1 and R?1 have the values of R? et R? or represent an alkyl substituted with a fluorine, with OR5 or NR?R? as defined above; e) CO2Ra, in which Ra represents hydrogen, alkyl or a carboxyl-protecting group, and also novel intermediate compounds. The quinolines of formula (I) are intermediates useful in the preparation of compounds having antibacterial activity, described in particular in applications WO 02/40474 or WO 02/72572.

Abstract: The present invention relates to compounds having the formula, and pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted pyridyl, ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted C(?O)NR6, wherein R6 is lower alkyl or cyclopropyl. The compounds are surprisingly advantageous in preparing pharmaceutical compositions for treating p38 kinase related conditions and/or in methods of treating conditions associated with the activity of p38 kinase in a patient.

Abstract: In various aspects, the present invention relates to non-peptidic compounds, which modulate calcitonin and amylin receptor activity; to processes for the preparation of some such compounds; and to pharmaceutical compositions including such compounds. Compounds of the invention are useful as calcitonin and/or amylin agonists and in the treatment of bone diseases and metabolic diseases.

Abstract: A process for making energetic cured binders by making poly-tetrazoles to produce multi-functional tetrazole polyols for producing tetrazole base polymers. Embodiments of the present invention relate generally to a process for preparation of a monomer including reacting an effective amount of nitrile(s) with inorganic azide and a divalent zinc salt in a first solvent, cooling to room temperature producing poly tetrazole, purifying the poly tetrazole by precipitation in a second solvent, and reacting an effective amount of the purified poly tetrazole with a third solvent, a soluble reversible or non-reversible base, and 2-chloro-ethanol, cooling to room temperature producing tetrazole polyol.

Abstract: What is described are 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazoles of the formula (I) and their use as herbicides. In this formula (I), R1, R2, R3, R4 and R5 are various radicals.

Abstract: Combinatorial libraries that contains various different 4, 5 fused 3-substituted-2-pyrrolocarboxylic acids for screening pharmacological activity and methods of synthesizing said libraries.